Survival trends for patients with AIDS

Area of Science:

• Epidemiology
• Public Health
• Infectious Diseases

Background:

• Acquired immunodeficiency syndrome (AIDS) presented a significant public health challenge with evolving patient survival rates.
• Understanding survival trends is crucial for assessing treatment efficacy and disease progression.

Purpose of the Study:

• To evaluate trends in survival length for patients diagnosed with acquired immunodeficiency syndrome (AIDS).
• To identify factors influencing survival, including diagnosis, age, year of diagnosis, and specific therapies like zidovudine.

Main Methods:

• Analysis of 4323 AIDS cases reported in San Francisco from July 1981 to December 1987.
• Prospective follow-up of patients through December 1988 to determine survival outcomes.
• Proportional hazards analyses to identify significant predictors of survival.

Main Results:

• Overall median survival was 12.5 months, with a 5-year survival rate of 3.4%.
• Significantly improved survival was noted for patients diagnosed with Pneumocystis carinii pneumonia in 1986-1987.
• Survival declined for Kaposi's sarcoma patients, while remaining unchanged for other opportunistic infections.
• Zidovudine therapy was a significant predictor of improved survival in a subset of patients.

Conclusions:

• Survival following AIDS diagnosis has improved in recent years, particularly for those with Pneumocystis carinii pneumonia.
• Zidovudine therapy may be a contributing factor to the observed improvements in AIDS patient survival.
• Continued monitoring and research are essential to further enhance outcomes for individuals living with AIDS.